JAK2 exon12 has been identified by NGS with a 1.3% prevalence in idiopathic non-cirrhotic SVT and with 40% prevalence (two out of five cases) in triple-negative MPN-SVT, further strengthening the site-specific association of JAK2 mutations with SVT [78]. Here, JAK2 is linked to myeloproliferative neoplasm.